The response of CD4+ and CD8+ T cells harvested from the peripheral blood from PD-1 treated NSCLC (n = 27) and RCC (n = 28) patients to specific bacteria was associated with favorable clinical outcome. This evidence concerns the gene PDCD1 and renal cell carcinoma.